Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CD20/ALiCE, ACE18, YBL 031 + [1] |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Preclinical | KR | - |